Core Viewpoint - Baijia Pharmaceutical-B (02659.HK) has announced the launch of its IPO in Hong Kong, with shares expected to be listed on December 10 [1] Group 1: IPO Details - The company plans to issue a total of 37.9117 million shares, with 10% allocated for the Hong Kong offering and 90% for international offering [1] - The maximum offer price is set at HKD 26.38 per share [1] Group 2: Fund Utilization - The funds raised from the IPO will primarily be used for the research and commercialization of core products, as well as advancing existing pipelines and regulatory filings [1] - A portion of the funds will also be allocated to optimizing the synthetic biology technology platform and developing new drug candidates, aiming to strengthen the company's competitive position in four strategic therapeutic areas [1]
宝济药业-B启动港股招股 募资聚焦研发与产品落地
Zheng Quan Shi Bao Wang·2025-12-02 04:07